RetinalGenix Technologies to Participate at the 37th Annual Roth Conference

APOLLO BEACH, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), today announced it will participate at the 37^th Annual Roth Conference on March 16^th to 18^th. The Company will highlight its proprietary high-resolution, real-time retinal and ocular imaging and monitoring RetinalCam™, which is currently imaging patients and is in the prototype stage. RetinalCam™ may facilitate the detection of early biomarkers that could prevent possible future blindness or systemic disease. The Company is projecting to complete testing by Q2 2025, with the first device sales later in the year. RetinalGenix is also advancing its DNA/RNA/GPS™ Pharmaco-Genetic Mapping™ software to validate and guide the development of novel methods and therapeutic products.

Read more at globenewswire.com